Table 2.
Immunoreactivity and effect of neuraminidase treatment for KL-6 and sialyl-MUC1
| Tumor type | Makers | ||||
|---|---|---|---|---|---|
| KL-6 | Sialyl MUC1 | ||||
| Before neuraminidase treatment | After neuraminidase treatment | Before neuraminidase treatment | After neuraminidase treatment | ||
| Chromophobe renal cell carcinoma classic type (n=10) | 100a3 (3–3)b | 1001 (1–2) | 1002 (2.5–3) | 100 (0–0) | |
| Chromophobe renal cell carcinoma eosinophilic variant (n=4) | 1003 (2–3) | 1002 (1–3) | 1002 (1.5–2.5) | 250 (0–0.5) | |
| Oncocytoma (n=7) | 1003 (2.5–3) | 1002 (1.25–2) | 1003 (2.25–3) | 28.60 (0–0.75) | |
| Clear renal cell carcinoma (n=9) | 1003 (2.5–3) | 55.61 (0–1) | 1001 (1–2) | 00 (0–0) | |
a Frequency (%) of positive specimens.
b Median score with the interquartile range in parenthesis.